Abstract

This review mainly focuses on the dosimetry methodology which includes consideration of the number and time points of scans, imaging methodology, methods for integrating time-activity curves and calculating absorbed doses. ¹⁷⁷Lu-labelled compounds show many advantages for dosimetry assessments due to attractive physical properties which comprise low abundance of photons for sufficient post-therapy imaging, a clearly separated gamma peak at 208 keV, and a low range of beta particles. The most up-to-date results of absorbed dose calculations for the kidneys, bone marrow, and tumors are provided. The absorbed doses reported for radiopeptide therapies using ¹⁷⁷Lu labelled compounds taken from clinical studies show a high variability, presumably because of the different applied methodologies.

Keywords: ¹⁷⁷Lu, dosimetry, molecular radiotherapy, radiopeptide therapy.

Graphical Abstract